GlassScriptPhysician profile
Ivana Paz
NPI 1346474632
$2,834.14
in general payments reported to CMS, 2019-2025
25 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $474 · 2022: $627 · 2023: $763 · 2024: $456 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.99 | 2021-2023 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $444.95 | 2021-2025 | Airsupra, Breztri |
| Amgen INC. | $265.85 | 2021-2025 | Evenity, Otezla, Repatha |
| Atricure, INC. | $191.03 | 2023 | |
| Edwards Lifesciences Corporation | $180.89 | 2025 | |
| Novo Nordisk INC | $178.96 | 2022 | |
| Pfizer INC. | $169.91 | 2021-2024 | |
| Glaxosmithkline, LLC. | $141.37 | 2021-2023 | Trelegy Ellipta |
| Janssen Scientific Affairs, LLC | $126.39 | 2023 | Xarelto |
| Teleflex LLC | $86.13 | 2024 | Urolift |
| Exact Sciences Corporation | $80.43 | 2025 | The Cologuard Plus Collection Kit |
| Axonics, INC. | $60.18 | 2023-2024 | Axonics |
| Novartis Pharmaceuticals Corporation | $59.29 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $54.25 | 2021-2025 | Capvaxive, Gardasil 9 |
| Nevro Corp. | $39.06 | 2023 | Senza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $31.23 | 2021-2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $26.00 | 2022 | |
| Lilly USA, LLC | $25.75 | 2022 | |
| Amarin Pharma, INC. | $24.04 | 2021 | |
| Dexcom, INC. | $20.44 | 2022 | |
| Abbott Laboratories | $19.41 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $17.41 | 2024 | Nexletol |
| Corcept Therapeutics | $15.93 | 2025 | Korlym |
| Aimmune Therapeutics, INC. | $15.32 | 2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $14.93 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivana Paz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.